YemenTuberculosis profile
Population  2016 28 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 1.9 (1.3–2.6) 6.9 (4.9–9.3)
Mortality (HIV+TB only) 0.026 (<0.01–0.053) 0.09 (0.03–0.19)
Incidence  (includes HIV+TB) 13 (12–15) 48 (42–54)
Incidence (HIV+TB only) 0.091 (0.059–0.13) 0.33 (0.21–0.47)
Incidence (MDR/RR-TB)** 0.36 (0.18–0.55) 1.3 (0.65–2)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.71 (0.62–0.8) 4.8 (4.2–5.4) 5.5 (4.8–6.2)
Males 0.74 (0.64–0.84) 7 (6.1–7.9) 7.7 (6.7–8.7)
Total 1.4 (1.3–1.6) 12 (10–13) 13 (12–15)
TB case notifications, 2016  
Total cases notified 9 498
Total new and relapse 9 412
          - % tested with rapid diagnostics at time of diagnosis 9%
          - % with known HIV status 16%
          - % pulmonary 65%
          - % bacteriologically confirmed among pulmonary 55%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 71% (63–82)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.15 (0.1–0.2)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 40 3%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  190
(100–280)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.92–3.7) 18% (8.7–28)  
% notified tested for rifampicin resistance 7% 43% 810
MDR/RR-TB cases tested for resistance to second-line drugs   0
Laboratory-confirmed cases MDR/RR-TB: 48, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 33, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 87% 7 654
Previously treated cases, excluding relapse, registered in 2015 78% 45
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014 71% 41
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 5.6
Funding source: 0% domestic, 38% international, 62% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-12-15 Data: www.who.int/tb/data